Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (35 ops.)
Latest filing published 06 Aug 2026 for PTC Therapeutics, INC., €613k.
Filing timeline
BuySaleMatthew B. Klein
Insider track record
Disclosed buys
0
Disclosed sells
35
Signal history
Matthew B. Klein: trading record in brief
Matthew B. Klein, CHIEF EXECUTIVE OFFICER of PTC Therapeutics, Inc. (51 filings) and a director of ClearPoint Neuro, Inc. (6), filed 35 sales out of 57 filings, worth EUR 6,283,381 in total with a median of EUR 147,776. There is no purchase. The three largest are dated August 4, 2026 (EUR 612,849), December 30, 2025 (EUR 526,584) and August 5, 2025 (EUR 479,858).
The rest of the record is 16 share grants and 6 option exercises. The yearly pace runs from 1 filing in 2020 to 12 in 2021 and in 2025, then 13 in 2026, with 5 to 7 a year between 2022 and 2024. Fifteen filings, 10 of them sales, fall in the last twelve months.
At PTC Therapeutics, Klein's trades sit near those of several colleagues, all in the same direction: 30 within 30 days of Eric Pauwels, 29 of Mark Elliott Boulding, 25 of Neil Gregory Almstead, 23 of Christine Marie Utter and 18 of Lee Scott Golden. Filings are published a median of 2 days after the trade.
Companies and markets linked to Matthew B. Klein
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations57 total
10,292 shares@ US$68.570.013% mcap14.5% of flowCommon StockSEC:0001808968-26-000017:0
16,000 shares@ US$11.590.039% mcap100.0% of flowCommon StockSEC:0001193125-26-239431:0
12,417 sharesCommon StockSEC:0001193125-26-234577:0
12,500 shares0Common StockSEC:0001808968-26-000015:0
2,850 shares@ US$70.910.0027% mcap4.1% of flowCommon StockSEC:0001808968-26-000013:0
2,662 shares@ US$64.082.1% of flowCommon StockSEC:0001808968-26-000011:1
12,500 shares0Common StockSEC:0001808968-26-000011:0
7,371 shares@ US$69.3610.2% of flowCommon StockSEC:0001808968-26-000009:0
2,514 shares@ US$76.453.9% of flowCommon StockSEC:0001808968-26-000007:0
3,016 shares@ US$77.482.8% of flowCommon StockSEC:0001808968-26-000005:1
5,149 shares@ US$76.958.0% of flowCommon StockSEC:0001808968-26-000005:0
63,000 shares0Common StockSEC:0001808968-26-000003:0
8,089 shares@ US$76.6412.5% of flowCommon StockSEC:0001808968-26-000001:0
3,428 shares@ US$79.073.3% of flowCommon StockSEC:0001808968-25-000003:1
15,625 shares0Common StockSEC:0001808968-25-000003:0
10,739 shares@ US$51.746.7% of flowCommon StockSEC:0001415889-25-021130:1
75,000 shares0Common StockSEC:0001415889-25-021130:0
21,093 sharesCommon StockSEC:0000950170-25-074448:0
2,804 shares@ US$48.7362.9% of flowCommon StockSEC:0001415889-25-011290:0
3,895 shares@ US$50.122.6% of flowCommon StockSEC:0001415889-25-005136:1
3,897 shares@ US$50.0964.4% of flowCommon StockSEC:0001415889-25-005136:0
2,402 shares@ US$44.501.4% of flowCommon StockSEC:0001415889-25-001293:1
2,142 shares@ US$45.342.2% of flowCommon StockSEC:0001415889-25-001293:0
70,000 shares0Common StockSEC:0001415889-25-001015:0
8,279 shares@ US$45.168.5% of flowCommon StockSEC:0001415889-25-000580:0
25 of 57 declarations
